AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26232903 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention (four calls for A1c >7%-9%, eight calls for A1c >9%)
Number of subjects: 941
Study 26232903 — intervention group
Group type: COMPARATOR
Intervention: Print-only intervention
Number of subjects: 941
Study 26232903 — intervention group
Group type: COMPARATOR
Intervention: Both groups (telephone and print-only)
Number of subjects: 941
Study 23063337 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Number of subjects: 2008
Study 23063337 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel implant
Number of subjects: 2008
Study 23063337 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD (TCu380A)
Number of subjects: 2008
Study 22263337 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizer gel (DG; 5% potassium nitrate and 2% sodium fluoride) applied for 10 minutes before bleaching treatment with 16% carbamide peroxide (CP)
Number of subjects: 60
Study 22263337 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied for 10 minutes before bleaching treatment with 16% carbamide peroxide (CP)
Number of subjects: 60
Study 19805679 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 2616
Study 16384850 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH (rhTSH) preparation with 3.7 GBq (100 mCi) 131I in euthyroid patients
Number of subjects: 45
Study 16384850 — intervention group
Group type: COMPARATOR
Intervention: Conventional remnant ablation in hypothyroid state with 3.7 GBq (100 mCi) 131I
Number of subjects: 45
Study 16384850 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life in euthyroid group
Number of subjects: 45
Study 16384850 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose to blood in euthyroid group
Number of subjects: 45
Study 15015442 — intervention group
Group type: EXPERIMENTAL
Intervention: Kebimin decoction (KD), given one dose per day for 10 days, with 1-3 courses given successively.
Number of subjects: 82
Study 15015442 — intervention group
Group type: COMPARATOR
Intervention: Xinfang Rhinitis capsule, treated for 30 days.
Number of subjects: 82
Study 15015442 — intervention group
Group type: EXPERIMENTAL
Intervention: Kebimin decoction (KD)
Number of subjects: 82
Study 15015442 — intervention group
Group type: COMPARATOR
Intervention: Control group (Xinfang Rhinitis capsule)
Number of subjects: 82
Study 11038993 — intervention group
Group type: EXPERIMENTAL
Intervention: Tong Xin Luo (TXL) capsule
Number of subjects: 36
Study 11038993 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 36
Study 9210889 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP-based chemotherapy (CTX)
Number of subjects: 0
Study 9210889 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT-11 with mitomycin-C regimen
Number of subjects: 0
Study 9210889 — intervention group
Group type: COMPARATOR
Intervention: CDDP-based regimen
Number of subjects: 0
Study 8454142 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses performing sigmoidoscopy
Number of subjects: 10
Study 8454142 — intervention group
Group type: EXPERIMENTAL
Intervention: Resident physicians performing sigmoidoscopy
Number of subjects: 10
Study 8454142 — intervention group
Group type: COMPARATOR
Intervention: Nurses and resident physicians
Number of subjects: 10
Study 3766171 — intervention group
Group type: COMPARATOR
Intervention: Thermoneutral conditions (25 degrees C)
Number of subjects: 8
Study 3766171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot dry environment (40 degrees C)
Number of subjects: 8
Study 29464379 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-fampridine
Number of subjects: 32
Study 27996108 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hormonal contraceptives
Number of subjects: 830
Study 27996108 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at menarche of 13 and older
Number of subjects: 830
Study 27996108 — intervention group
Group type: EXPERIMENTAL
Intervention: Last pregnancy after age 35
Number of subjects: 830
Study 27996108 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproductive period
Number of subjects: 830
Study 25093539 — intervention group
Group type: EXPERIMENTAL
Intervention: Any type of intervention (different forms of feedback)
Number of subjects: 166
Study 25093539 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 166
Study 25093539 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' driving behavior
Number of subjects: 166
Study 25093539 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of parents' commitment to safety
Number of subjects: 166
Study 25093539 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 166
Study 22451470 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor 2 (CRP, IL‐1ra, IL‐6)
Number of subjects: 179
Study 22451470 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference
Number of subjects: 179
Study 22451470 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and abdominal adiposity
Number of subjects: 179
Study 19581118 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-7 (daunorubicin, cytarabine, and cladribine)
Number of subjects: 309
Study 19581118 — intervention group
Group type: COMPARATOR
Intervention: DA-7 (daunorubicin and cytarabine)
Number of subjects: 309
Study 18828769 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab and belatacept therapy
Number of subjects: 0
Study 18828769 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 18828769 — intervention group
Group type: EXPERIMENTAL
Intervention: Basiliximab
Number of subjects: 0
Study 18828769 — intervention group
Group type: COMPARATOR
Intervention: CNI (Calcineurin Inhibitor)
Number of subjects: 0
Study 16583932 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg capsules once daily with the evening meal for 8 weeks
Number of subjects: 67
Study 16583932 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules once daily with the evening meal for 8 weeks
Number of subjects: 67
Study 16583932 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 67
Study 16583932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 12362101 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg q.d.
Number of subjects: 1052
Study 12362101 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg q.d.
Number of subjects: 1052
Study 12362101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1052
Study 12362101 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 800 mg t.i.d.
Number of subjects: 1052
Study 12362101 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg b.i.d.
Number of subjects: 1052
Study 9925903 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of sucrose (0.05 ml of 24% sucrose solution administered three times)
Number of subjects: 48
Study 9925903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of sucrose (0.05 ml of 24% sucrose solution for the first dose)
Number of subjects: 48
Study 9925903 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile water administered three times)
Number of subjects: 48
Study 7559180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone bursts of 250 Hz
Number of subjects: 0
Study 7559180 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone bursts of 4000 Hz
Number of subjects: 0
Study 7559180 — intervention group
Group type: COMPARATOR
Intervention: Tone bursts of 250 Hz and 4000 Hz
Number of subjects: 0
Study 2107117 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study 2107117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6988173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clenbuterol at 20 to 30 micrograms 3-times daily
Number of subjects: 16
Study 6988173 — intervention group
Group type: COMPARATOR
Intervention: Oral terbutaline at 2.5 to 5 mg 3-times daily
Number of subjects: 16
Study 28251804 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily micronutrient-rich snack containing green leafy vegetables, fruit, and milk
Number of subjects: 6513
Study 28251804 — intervention group
Group type: COMPARATOR
Intervention: Snack made from lower-micronutrient vegetables
Number of subjects: 6513
Study 28251804 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily micronutrient-rich snack
Number of subjects: 6513
Study 26394649 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine anhydrous (CAF) 300 mg flat dose (3-5 mg/kg bodyweight)
Number of subjects: 54
Study 26394649 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee (COF) 8.9 g (303 mg caffeine)
Number of subjects: 54
Study 26394649 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) 3.8 g non-caloric flavouring
Number of subjects: 54
Study 23676636 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 1 year (TP1)
Number of subjects: 250
Study 23676636 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (after alendronate)
Number of subjects: 250
Study 23676636 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 250
Study 23676636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TP2 baseline necessity scores
Number of subjects: 250
Study 23676636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concerns about medication scores
Number of subjects: 250
Study 23676636 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher NCD scores
Number of subjects: 250
Study 22465268 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg
Number of subjects: 50
Study 20035910 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg orally
Number of subjects: 59
Study 20035910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 17099306 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuchina 10% (ExSept Plus) for exit-site care
Number of subjects: 0
Study 17099306 — intervention group
Group type: EXPERIMENTAL
Intervention: Amuchina 5% (ExSept) for exit-site care
Number of subjects: 0
Study 17099306 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine for exit-site care
Number of subjects: 0
Study 17099306 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine for exit-site care
Number of subjects: 0
Study 17099306 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic chloroxidizing solutions (Amuchina 10% and Amuchina 5%) for exit-site care
Number of subjects: 0
Study 16158445 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg caffeine
Number of subjects: 48
Study 16158445 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 48
Study 16158445 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 48
Study 16158445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 11911996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynil estradiol (EE) 50 microg/day
Number of subjects: 25
Study 11911996 — intervention group
Group type: COMPARATOR
Intervention: Pentagastrin 30 microg iv bolus
Number of subjects: 25
Study 10333820 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide-simethicone (2 mg loperamide and 125 mg simethicone)
Number of subjects: 493
Study 10333820 — intervention group
Group type: COMPARATOR
Intervention: Loperamide alone (2 mg)
Number of subjects: 493
Study 10333820 — intervention group
Group type: COMPARATOR
Intervention: Simethicone alone (125 mg)
Number of subjects: 493
Study 10333820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 493
Study 12165787 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg/kg)
Number of subjects: 71
Study 12165787 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 71
Study 1888051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal Doppler-derived cardiac output (DdCO)
Number of subjects: 33
Study 1888051 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution cardiac output (TdCO)
Number of subjects: 33
Study 1888051 — intervention group
Group type: COMPARATOR
Intervention: Comparison of DdCO and TdCO
Number of subjects: 33
Study 6358654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) alone
Number of subjects: 62
Study 6358654 — intervention group
Group type: COMPARATOR
Intervention: Conventional immunosuppression (low-dose steroids)
Number of subjects: 62
Study 6358654 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA) with low-dose steroids
Number of subjects: 62
Study 31930897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture under hypnosis (first-time)
Number of subjects: 52
Study 31930897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture after wakened-up (second-time)
Number of subjects: 52
Study 31930897 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture in clear consciousness (first-time, control group)
Number of subjects: 52
Study 31930897 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture after hypnosis (second-time, control group)
Number of subjects: 52
Study 31930897 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture after hypnosis (second-time) vs. first-time acupuncture (control group)
Number of subjects: 52
Study 31930897 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture under hypnosis (first-time) vs. control group (first-time)
Number of subjects: 52
Study 31930897 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture after hypnosis (second-time) vs. control group (second-time)
Number of subjects: 52
Study 31400624 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive riluzole
Number of subjects: 66
Study 29530340 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical SR-T100 gel
Number of subjects: 113
Study 29530340 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 113
Study 26174046 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (handoff skills training workshop)
Number of subjects: 0
Study 26174046 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time handoffs by intervention students
Number of subjects: 0
Study 26174046 — intervention group
Group type: COMPARATOR
Intervention: Untrained control students
Number of subjects: 0
Study 26799887 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group adjunct to mHealth physical activity intervention
Number of subjects: 30
Study 22652361 — intervention group
Group type: EXPERIMENTAL
Intervention: ePHF for 3 months
Number of subjects: 4
Study 22652361 — intervention group
Group type: EXPERIMENTAL
Intervention: ePHF for 8 months
Number of subjects: 4
Study 22652361 — intervention group
Group type: EXPERIMENTAL
Intervention: ePHF for 1 month
Number of subjects: 4
Study 22652361 — intervention group
Group type: COMPARATOR
Intervention: CMF for 8 months
Number of subjects: 4
Study 20012296 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 37
Study 20012296 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (Control)
Number of subjects: 37
Study 18797469 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with uracil-tegafur (UFT)
Number of subjects: 0
Study 18797469 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 15833522 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of 7.5 mg intranasal PT-141 and 25 mg sildenafil
Number of subjects: 19
Study 15833522 — intervention group
Group type: COMPARATOR
Intervention: 25 mg sildenafil and intranasal placebo spray
Number of subjects: 19
Study 15833522 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet and intranasal placebo spray
Number of subjects: 19
Study 11805693 — intervention group
Group type: EXPERIMENTAL
Intervention: Belt (10 mm Hg)
Number of subjects: 11
Study 11805693 — intervention group
Group type: EXPERIMENTAL
Intervention: Belt (20 mm Hg)
Number of subjects: 11
Study 11805693 — intervention group
Group type: COMPARATOR
Intervention: No belt (0 mm Hg)
Number of subjects: 11
Study 10365639 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL)
Number of subjects: 66
Study 10365639 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) at doses less than 0.2 mg/kg
Number of subjects: 66
Study 10365639 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (HAL) at doses more than 0.2 mg/kg
Number of subjects: 66
Study 8748428 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of alprazolam twice daily
Number of subjects: 48
Study 8748428 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of nefazodone twice daily
Number of subjects: 48
Study 8748428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 mg of alprazolam and 200 mg of nefazodone twice daily
Number of subjects: 48
Study 8748428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 2035569 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile water blocks
Number of subjects: 272
Study 2035569 — intervention group
Group type: COMPARATOR
Intervention: Saline solution blocks
Number of subjects: 272
Study 6138087 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 15 mg
Number of subjects: 0
Study 6138087 — intervention group
Group type: COMPARATOR
Intervention: Midazolam 30 mg
Number of subjects: 0
Study 6138087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31913428 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Janus kinase 1 inhibitor abrocitinib
Number of subjects: 0
Study 31913428 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31359782 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified recipes
Number of subjects: 52
Study 31359782 — intervention group
Group type: COMPARATOR
Intervention: Control recipes
Number of subjects: 52
Study 28608261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0-mm locking plates
Number of subjects: 87
Study 28608261 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2.0- or 2.4-mm plates
Number of subjects: 87
Study 26689589 — intervention group
Group type: EXPERIMENTAL
Intervention: E2012 (20 or 80 mg/kg)
Number of subjects: 7
Study 25117805 — intervention group
Group type: EXPERIMENTAL
Intervention: MAINTAIN intervention for 40 weeks, followed by 16 weeks of no intervention contact
Number of subjects: 230
Study 25117805 — intervention group
Group type: COMPARATOR
Intervention: Usual care for 56 weeks
Number of subjects: 230
Study 22003053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg single dose)
Number of subjects: 48
Study 22003053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day for 21 days)
Number of subjects: 48
Study 22003053 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day for 21 days) and Celecoxib (100 mg bid)
Number of subjects: 48
Study 22003053 — intervention group
Group type: COMPARATOR
Intervention: Placebo (21 days)
Number of subjects: 48
Study 19916262 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fluence high repetition rate diode laser (5-10 J/cm2, 10 Hz, Soprano XL in SHR mode)
Number of subjects: 25
Study 19916262 — intervention group
Group type: COMPARATOR
Intervention: High fluence low repetition rate diode laser (25-40 J/cm2, LightSheer ET)
Number of subjects: 25
Study 17263737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal clonidine 4 microg/kg
Number of subjects: 40
Study 17263737 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine 4 microg/kg
Number of subjects: 40
Study 17263737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal clonidine
Number of subjects: 40
Study 17263737 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine
Number of subjects: 40
Study 17877886 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic therapy with antiviral medications (1-, 2-, and 3-day courses compared to standard 5-day regimens)
Number of subjects: 0
Study 17877886 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive antiviral therapy
Number of subjects: 0
Study 17877886 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiherpes therapy in HIV-positive patients
Number of subjects: 0
Study 15376212 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirator
Number of subjects: 22
Study 15376212 — intervention group
Group type: COMPARATOR
Intervention: Unprotected
Number of subjects: 22
Study 10867091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester spread (5.1 g/day)
Number of subjects: 167
Study 10867091 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 167
Study 9772413 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25 mg initial dose, 12.5 mg 2 hours later, and then 12.5 mg three times daily for 4 weeks)
Number of subjects: 14962
Study 9772413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14962
Study 8246027 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus levamisole
Number of subjects: 1025
Study 8246027 — intervention group
Group type: COMPARATOR
Intervention: Levamisole alone
Number of subjects: 1025
Study 8246027 — intervention group
Group type: COMPARATOR
Intervention: Observation only (untreated controls)
Number of subjects: 1025
Study 3698180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide
Number of subjects: 78
Study 3698180 — intervention group
Group type: COMPARATOR
Intervention: High-dose IV dexamethasone
Number of subjects: 78
Study 3698180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (HD-CDDP group)
Number of subjects: 78
Study 3698180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (LD-CDDP group)
Number of subjects: 78
Study 3698180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (LD-CDDP combination chemotherapy)
Number of subjects: 78
Study 3698180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IV metoclopramide (previously untreated patients)
Number of subjects: 78
Study 3698180 — intervention group
Group type: COMPARATOR
Intervention: High-dose IV dexamethasone (LD-CDDP monochemotherapy)
Number of subjects: 78